Abeona Therapeutics Inc

$6.56
(as of Apr 30, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Abeona Therapeutics Inc

Stock Price
$6.56
Ticker Symbol
ABEO
Exchange
NASDAQ

Industry Information for Abeona Therapeutics Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Abeona Therapeutics Inc

Website
https://www.abeonatherapeutics.com
Country
USA
Full Time Employees
136

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Fundamentals for Abeona Therapeutics Inc

Market Capitalization
$258,639,472
EBITDA
$-62,207,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-1.55
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
48,799,900
Percent Owned by Insiders
6.59%
Percent Owned by Institutions
68.21%
52-Week High
52-Week Low

Technical Indicators for Abeona Therapeutics Inc

50-Day Moving Average
200-Day Moving Average
RSI
ATR
0.5

Analyst Ratings for Abeona Therapeutics Inc

Strong Buy
5
Buy
1
Hold
0
Sell
0
Strong Sell
0

News About Abeona Therapeutics Inc

Apr 29, 2025, 6:00 AM EST
- ZEVASKYN fills a critical need for people living with RDEB, a debilitating dermatological condition with no cure - See more.
Apr 1, 2025, 7:30 AM EST
CLEVELAND, April 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. See more.
Mar 20, 2025, 7:30 AM EST
FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025 See more.
Feb 3, 2025, 7:30 AM EST
CLEVELAND, Feb. See more.